Omics Research // PROTEOMICS
Olink® Target 48
Improve disease detection, enabling faster, better-informed decisions in human and mouse protein biomarker research.
Available Panels
Target 48 Cytokine
45 cytokine biomarkers that can be evaluated by relative or absolute quantification. Ideal for inflammation-related studies.
Target 48 Mouse Cytokine
43 biomarkers applicable to preclinical and translational research, particularly in oncology, inflammation, and immunology.
SAMPLE REPORT
What Will You Do With Your Data?
With newly designed reports from Psomagen, access a new level of data analysis and confidence in your results. Now including a thorough experimental summary complete with MDS and Box plots, data calculations with formulas, and a heatmap so you can assess your results before you pull out your statistical tools.
Target 48 Best Practices
Minimum Sample Size
40 µL
Sample Type
Plasma and serum are fully validated sample types.
Other biological fluids, as well as tissue and cell lysates, may also be suited for analysis.
Kit Size
40 samples per kit
Instrumentation
Olink Signature Q100
Bioinformatic Analysis Options
- Normalized Protein Expression (NPX)
- Absolute Protein Quantitation
- Statistical Analyses
- Data Visualization
Our Target 48 Workflow
We're Olink® Certified!
We are a certified service provider for all available Olink panels. To learn more about our certifications, visit the Olink® service provider website.
See how we did — download our Target 48 Concordance Test Report.

Thoughts from our experts
Proteomics Research: the Role of Cytokines in Disease
Proteomics and inflammation research are key ways to identify disease biomarkers and understand inflammation. Because cytokines play an important role in immune response, many researchers have begun to investigate manipulating cytokine actions for therapeutic purposes.
More Proteomics at Psomagen
We offer all Olink Proteomics platforms in our labs, allowing you to select the coverage and cost necessary for your project. Click the links below to learn more about: